|

Met Non Small Cell Cancer Registry (MOMENT)

RECRUITINGSponsored by EMD Serono Research & Development Institute, Inc.
Actively Recruiting
SponsorEMD Serono Research & Development Institute, Inc.
Started2022-10-04
Est. completion2028-04-28
Eligibility
Healthy vol.Accepted
Locations3 sites
View on ClinicalTrials.gov →

NCT05376891

Summary

The purpose of this multi-national disease registry is to collect prospectively (with longitudinal follow-up) high-quality, standardized, and contemporaneous data to capture changes in the non-small cell lung cancer (NSCLC) treatment landscape and outcomes over time. The registry will capture data on participants; demographic, clinical characteristics (including biomarker data), treatment patterns, and effectiveness and safety outcomes for advanced NSCLC with mesenchymal-epithelial transition exon 14 (METex14) participants treated with systemic therapy.

Eligibility

Healthy volunteers accepted
Inclusion Criteria:

* Participants who signed ICF
* Participants with advanced stage (stages IIIB-IV) NSCLC (all histologies) and Confirmed METex14 skipping alterations (by valid assay)
* Participants who are starting or are already being treated with systemic therapy

Exclusion Criteria:

* Participants who are enrolled in a clinical trial

Conditions1

Cancer

Locations3 sites

Florida

1 site
Holy Cross Health
Fort Lauderdale, Florida, 33308-4603
guchuan@hotmail.com

Ohio

1 site
The Ohio State University Wexner Medical Center
Columbus, Ohio, 43221
david.carbone@osumc.edu

Tennessee

1 site
Vanderbilt University Medical Center
Nashville, Tennessee, 37212

Browse More Trials

Cancer trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.